Investigating cell therapy for inflammatory bowel disease

References

• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727. doi:10.1038/nrgastro.2015.150.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621. doi:10.1146/annurev-immunol-030409-101225.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–133. doi:10.1097/00054725-199905000-00008.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659–quiz660. doi:10.1038/ajg.2011.73.
   Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–346. doi:10.1002/ibd.21253.
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422. doi:10.1053/j.gastro.2007.05.051.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–3. doi:10.1016/j.cgh.2010.12.028.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635. doi:10.1136/gutjnl-2012-302830.
   PubMed Web of Science ®Google Scholar
• Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3:419–428. doi:10.1177/2050640615590302.
   PubMed Web of Science ®Google Scholar
• Pinchuk IV, Mifflin RC, Saada JI, et al. Intestinal mesenchymal cells. Curr Gastroenterol Rep. 2010;12:310–318. doi:10.1007/s11894-010-0135-y.
   PubMedGoogle Scholar
• Powell DW, Pinchuk IV, Saada JI, et al. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol. 2011;73:213–237. doi:10.1146/annurev.physiol.70.113006.100646.
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Kanai T, Makita S, et al. Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology. 2007;132:176–189. doi:10.1053/j.gastro.2006.10.035.
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Kanai T, Kameyama K, et al. Long-lived colitogenic CD4+ memory T cells residing outside the intestine participate in the perpetuation of chronic colitis. J Immunol. 2009;183:5059–5068. doi:10.4049/jimmunol.0900838.
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Oyama Y, et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood. 2003;101:2064–2066. doi:10.1182/blood-2002-07-2122.
   PubMed Web of Science ®Google Scholar
• Kreisel W, Potthoff K, Bertz H, et al. Complete remission of Crohn’s disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 2003;32:337–340. doi:10.1038/sj.bmt.1704134.
   PubMed Web of Science ®Google Scholar
• Scimè R, Cavallaro AM, Tringali S, et al. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy. Inflamm Bowel Dis. 2004;10:892–894. doi:10.1097/00054725-200411000-00027.
   PubMed Web of Science ®Google Scholar
• Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology. 2005;128:552–563. doi:10.1053/j.gastro.2004.11.051.
   PubMed Web of Science ®Google Scholar
• Lashner BA. Autologous hematopoietic stem cell transplantation for Crohn’s disease: high risk for a high reward. Inflamm Bowel Dis. 2005;11:778–779. doi:10.1097/01.MIB.0000171286.88690.ec.
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut. 2008;57:211–217. doi:10.1136/gut.2007.128694.
   PubMed Web of Science ®Google Scholar
• Clerici M, Cassinotti A, Onida F, et al. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn’s disease. Dig Liver Dis. 2011;43:946–952. doi:10.1016/j.dld.2011.07.021.
   PubMedGoogle Scholar
• Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116:6123–6132. doi:10.1182/blood-2010-06-292391.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Duijvestein M, Zelinkova Z, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn’s disease. J Crohns Colitis. 2011;5:543–549. doi:10.1016/j.crohns.2011.05.004.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Ansari A, Sachchithanantham S, et al. Autologous stem cell transplantation in severe treatment-resistant Crohn’s disease: long-term follow-up of UK patients treated on compassionate basis. QJM. 2014;107:871–877. doi:10.1093/qjmed/hcu095.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, Rovira M, Marín P, et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn’s disease. Gut. 2015. doi:10.1136/gutjnl-2015-309836. [Epub ahead print]
   Google Scholar
• Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314:2524–2534. doi:10.1001/jama.2015.16700.
   PubMed Web of Science ®Google Scholar
• Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923–940. doi:10.1161/CIRCRESAHA.111.243147.
   PubMed Web of Science ®Google Scholar
• Onishi R, Ohnishi S, Higashi R, et al. Human amnion-derived mesenchymal stem cell transplantation ameliorates dextran sulfate sodium-induced severe colitis in rats. Cell Transplant. 2015;24:2601–2614. doi:10.3727/096368915X687570.
   PubMed Web of Science ®Google Scholar
• Ishikane S, Ohnishi S, Yamahara K, et al. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells. 2008;26:2625–2633. doi:10.1634/stemcells.2008-0236.
   PubMed Web of Science ®Google Scholar
• Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252–260. doi:10.1038/nbt.2816.
   PubMed Web of Science ®Google Scholar
• Mahmoud EE, Kamei G, Harada Y, et al. Cell magnetic targeting system for repair of severe chronic osteochondral defect in a rabbit model. Cell Transplant. 2015. doi:10.3727/096368915X689613. [Epub ahead print]
   PubMedGoogle Scholar
• Karantalis V, Suncion-Loescher VY, Bagno L, et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. J Am Coll Cardiol. 2015;66:1990–1999. doi:10.1016/j.jacc.2015.08.879.
   PubMed Web of Science ®Google Scholar
• Casiraghi F, Perico N, Cortinovis M, et al. Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nat Rev Nephrol. 2016;12:241–253. doi:10.1038/nrneph.2016.7.
   PubMed Web of Science ®Google Scholar
• Chen C, Hou J. Mesenchymal stem cell-based therapy in kidney transplantation. Stem Cell Res Ther. 2016;7:16. doi:10.1186/s13287-016-0283-6.
   PubMed Web of Science ®Google Scholar
• Antunes MA, Laffey JG, Pelosi P, et al. Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem. 2014;115:1023–1032. doi:10.1002/jcb.24783.
   PubMed Web of Science ®Google Scholar
• Cai J, Wu Z, Xu X, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39:149–157. doi:10.2337/dc15-0171.
   PubMed Web of Science ®Google Scholar
• Guan L-X, Guan H, Li H-B, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015;9:1623–1630. doi:10.3892/etm.2015.2355.
   PubMed Web of Science ®Google Scholar
• Oraee-Yazdani S, Hafizi M, Atashi A, et al. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016;54:102–109. doi:10.1038/sc.2015.142.
   PubMed Web of Science ®Google Scholar
• Owen A, Newsome PN. Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt? Am J Physiol Gastrointest Liver Physiol. 2015;309:G791–800.
   PubMed Web of Science ®Google Scholar
• Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–250. doi:10.1007/s12185-015-1915-9.
   PubMed Web of Science ®Google Scholar
• Li J-F, Zhang D-J, Geng T, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23(Suppl 1):S113–S122. DOI:10.3727/096368913X673450.
   PubMed Web of Science ®Google Scholar
• Cras A, Farge D, Carmoi T, et al. Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Res Ther. 2015;17:301. doi:10.1186/s13075-015-0819-7.
   PubMed Web of Science ®Google Scholar
• Tanaka F, Tominaga K, Ochi M, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008;83:771–779. doi:10.1016/j.lfs.2008.09.016.
   PubMed Web of Science ®Google Scholar
• Parekkadan B, Upadhyay R, Dunham J, et al. Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes. Gastroenterology. 2011;140:966–975. doi:10.1053/j.gastro.2010.10.013.
   PubMed Web of Science ®Google Scholar
• Yabana T, Arimura Y, Tanaka H, et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol. 2009;218:350–359. doi:10.1002/path.2535.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Arimura Y, Yabana T, et al. Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. J Gastroenterol. 2011;46:143–152. doi:10.1007/s00535-010-0320-7.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Arimura Y, Nagaishi K, et al. Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors. J Gastroenterol. 2014;49:270–282. doi:10.1007/s00535-013-0895-x.
   PubMed Web of Science ®Google Scholar
• Nagaishi K, Arimura Y, Fujimiya M. Stem cell therapy for inflammatory bowel disease. J Gastroenterol. 2015;50:280–286. doi:10.1007/s00535-015-1040-9.
   PubMed Web of Science ®Google Scholar
• Sala E, Genua M, Petti L, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology. 2015;149:163–176.e20. doi:10.1053/j.gastro.2015.03.013.
   PubMed Web of Science ®Google Scholar
• Choi H, Lee RH, Bazhanov N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood. 2011;118:330–338. doi:10.1182/blood-2011-02-334870.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells J. 2006;24:74–85. doi:10.1634/stemcells.2004-0359.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–398. doi:10.1634/stemcells.2005-0008.
   PubMed Web of Science ®Google Scholar
• Casado JG, Tarazona R, Sanchez-Margallo FM. NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity. Stem Cell Rev. 2013;9:184–189. doi:10.1007/s12015-013-9430-y.
   PubMed Web of Science ®Google Scholar
• Ko IK, Kim B-G, Awadallah A, et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther. 2010;18:1365–1372. doi:10.1038/mt.2010.54.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Pène J, Moquet-Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302–312. doi:10.4049/jimmunol.0902007.
   PubMed Web of Science ®Google Scholar
• Prigione I, Benvenuto F, Bocca P, et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009;27:693–702. doi:10.1634/stemcells.2008-0687.
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Le Blanc K, Sundberg B, et al. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol. 2007;65:336–343. doi:10.1111/j.1365-3083.2007.01915.x.
   PubMed Web of Science ®Google Scholar
• Svobodova E, Krulova M, Zajicova A, et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev. 2012;21:901–910. doi:10.1089/scd.2011.0157.
   PubMed Web of Science ®Google Scholar
• Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59:1662–1669. doi:10.1136/gut.2010.215152.
   PubMed Web of Science ®Google Scholar
• Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64–71. doi:10.1016/j.cgh.2013.06.021.
   PubMed Web of Science ®Google Scholar
• Manieri NA, Mack MR, Himmelrich MD, et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis. J Clin Invest. 2015. DOI:10.1172/JCI81423–13.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788–798. doi:10.1136/gut.2011.237727.
   PubMed Web of Science ®Google Scholar
• Cho YB, Park KJ, Yoon SN, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4:532–537. doi:10.5966/sctm.2014-0199.
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Gallia A, Sgarella A, et al. Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. Mayo Clin Proc. 2015;90:747–755. doi:10.1016/j.mayocp.2014.12.011.
   PubMed Web of Science ®Google Scholar
• Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31:2575–2581. doi:10.1002/stem.1357.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014:1381–1392. doi:10.1136/gutjnl-2013-306709.
   PubMed Web of Science ®Google Scholar
• Barker N, Van De Wetering M, Clevers H. The intestinal stem cell. Genes Dev. 2008;22:1856–1864. doi:10.1101/gad.1674008.
   PubMed Web of Science ®Google Scholar
• Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2015;51:11–21. doi:10.1007/s00535-015-1098-4.
   PubMed Web of Science ®Google Scholar
• Sato T, Van Es JH, Snippert HJ, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2012;469:415–418. doi:10.1038/nature09637.
   Web of Science ®Google Scholar
• Shimizu H, Okamoto R, Ito G, et al. Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine. Peer J. 2014;2:e370. doi:10.7717/peerj.246.
   Google Scholar
• VanDussen KL, Carulli AJ, Keeley TM, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139:488–497. doi:10.1242/dev.076851.
   PubMed Web of Science ®Google Scholar
• Okamoto R, Tsuchiya K, Nemoto Y, et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol. 2009;296:G23–G35. doi:10.1152/ajpgi.90225.2008.
   Google Scholar
• Gregorieff A, Liu Y, Inanlou MR, et al. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature. 2015;526:715–718. doi:10.1038/nature15382.
   PubMed Web of Science ®Google Scholar
• Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–1772. doi:10.1053/j.gastro.2011.07.050.
   PubMed Web of Science ®Google Scholar
• Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265. doi:10.1038/nature07935.
   PubMed Web of Science ®Google Scholar
• Sato T, Clevers H, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013;340:1190–1194. doi:10.1126/science.1234852.
   PubMed Web of Science ®Google Scholar
• Vandussen K, Marinshaw JM, Shaikh N, et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64:911–920.
   PubMed Web of Science ®Google Scholar
• Middendorp S, Schneeberger K, Wiegerinck CL, et al. Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. Stem Cells. 2014;32:1083–1091. doi:10.1002/stem.1655.
   PubMed Web of Science ®Google Scholar
• Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med. 2012;18:618–623. doi:10.1038/nm.2695.
   PubMed Web of Science ®Google Scholar
• Fordham RP, Fordham RP, Yui S, et al. Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell. 2013;13:734–744. doi:10.1016/j.stem.2013.07.010.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Mizutani T, Mochizuki W, et al. Small intestinal stem cell identity is maintained with functional Paneth cells in heterotopically grafted epithelium onto the colon. Genes Dev. 2014;28:1752–1757. doi:10.1101/gad.245233.114.
   PubMed Web of Science ®Google Scholar
• Okamoto R, Watanabe M. Perspectives for regenerative medicine in the treatment of inflammatory bowel diseases. Digestion. 2015;92:73–77. doi:10.1159/000438663.
   PubMed Web of Science ®Google Scholar
• Matisz CE, Leung G, Reyes JL, et al. Adoptive transfer of helminth antigen-pulsed dendritic cells protects against the development of experimental colitis in mice. Eur J Immunol. 2015;45:3126–3139. doi:10.1002/eji.201545579.
   PubMed Web of Science ®Google Scholar
• Zigdon-Giladi H, Bick T, Lewinson D, et al. Co-transplantation of endothelial progenitor cells and mesenchymal stem cells promote neovascularization and bone regeneration. Clin Implant Dent Relat Res. 2015;17:353–359. doi:10.1111/cid.12104.
   PubMed Web of Science ®Google Scholar
• Vanikar AV, Dave SD, Thakkar UG, et al. Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int. 2010;2010:582382–582385. doi:10.4061/2010/582382.
   PubMed Web of Science ®Google Scholar
• Thakkar UG, Vanikar AV, Trivedi HL. Co-infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and bone marrow derived hematopoietic stem cells, a viable therapy for post-traumatic brachial plexus injury: a case report. Biomed J. 2014;37:237–240. doi:10.4103/2319-4170.132893.
   PubMedGoogle Scholar
• Chen Z, He X, He X, et al. Bone marrow mesenchymal stem cells ameliorate colitis-associated tumorigenesis in mice. Biochem Biophys Res Commun. 2014;450:1402–1408. doi:10.1016/j.bbrc.2014.05.144.
   PubMed Web of Science ®Google Scholar
• Nasuno M, Arimura Y, Nagaishi K, et al. Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Stem Cells. 2014;32:913–925. doi:10.1002/stem.1594.
   PubMed Web of Science ®Google Scholar
• Danese S, Malesci A, Vetrano S. Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut. 2011;60:1609–1610. doi:10.1136/gut.2011.237727.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2012;35:229–244. doi:10.1007/s00281-012-0352-6.
   PubMed Web of Science ®Google Scholar